# Effectiveness and Safety of BIO-11006 Inhalation Solution to Treat the Overproduction of Mucus and Inflammation in COPD

> **NCT00648245** · PHASE2 · COMPLETED · sponsor: **BioMarck Pharmaceuticals, Ltd.** · enrollment: 172 (estimated)

## Conditions studied

- COPD
- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** BIO-11006 Inhalation Solution
- **DRUG:** BIO-11006 Inhalation Solution
- **DRUG:** BIO-11006 Inhalation Solution
- **DRUG:** Placebo
- **DRUG:** BIO-11006

## Key facts

- **NCT ID:** NCT00648245
- **Lead sponsor:** BioMarck Pharmaceuticals, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2010-07
- **Final completion:** 2010-07
- **Target enrollment:** 172 (ESTIMATED)
- **Last updated:** 2011-02-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00648245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00648245, "Effectiveness and Safety of BIO-11006 Inhalation Solution to Treat the Overproduction of Mucus and Inflammation in COPD". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00648245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*